The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.
Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials
Abstract
Background Diabetes mellitus is a frequent comorbid condition in patients with chronic heart failure (CHF) and confers a worse prognosis. Furthermore, although patients with CHF derive considerable benefit from beta-blockers, these agents are thought by many physicians to be contraindicated in patients with diabetes mellitus. Most published studies on beta-blockers in CHF have been unable to reach definitive conclusions about the mortality benefits of these agents in patients with diabetes mellitus. We therefore performed a meta-analysis of beta-blocker trials that reported mortality outcomes in patients with diabetes mellitus who had CHF to pool all available trial evidence on the benefits (or otherwise) of these agents in this setting.Methods All-cause mortality data on patients with diabetes mellitus were obtained from all completed beta-blocker CHF randomized placebo-controlled trials involving >100 patients exposed to beta-blockers, in which outcomes in patients with diabetes mellitus were described. When events were not directly reported, risk ratios (RRs) were derived from analysis of figures and other manuscript data. Results were pooled with the Mantel-Haenszel method.Results A total of 24.6% of patients were reported to have diabetes mellitus in the 6 studies analyzed (Australia and New Zealand [ANZ]-Carvedilol, Beta-blocker Evaluation of Survival Trial [BEST], Carvedilol US Trials, Cardiac Insufficiency Bisoprolol Study [CIBIS-II], Carvedilol Prospective Randomized Cumulative Survival Trial [COPERNICUS], and Metoprolol Controlled-release Randomized Intervention Trial in Heart Failure [MERIT-HF]). Patients with diabetes mellitus had increased mortality rates overall compared with subjects without diabetes mellitus (RR, 1.25; 95% CI, 1.15-1.36; P <.001). Compared with placebo, beta-blocker therapy for CHF was beneficial in patients with diabetes mellitus (RR, 0.84; 95% CI, 0.73-0.96; P =.011) and in subjects without diabetes mellitus (RR, 0.72; 95% CI, 0.65-0.79; P <.001). The absolute risk reduction in mortality with beta-blocker therapy was greater in patients with heart failure but without diabetes mellitus than in patients with diabetes mellitus (P =.023).Conclusions Patients with diabetes mellitus and CHF appear to derive prognostic benefit from beta-blocker therapy, although the magnitude of that benefit is somewhat less than that observed in subjects without diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a meta-analysis of six trials, beta-blocker therapy reduced all-cause mortality in patients with T2DM (HR 0.84) similarly to those without T2DM (HR 0.72).156”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [156]
Citations
Cites
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
Lechat, P. P., Brunhuber, K., Hofmann, R., Kuhn, P., Nesser, H., Slany, J., Weihs, W., Wiedermann, C. J., Wimmer, H., van Mieghem, W., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,922
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,651
Diabetes and cardiovascular disease
Howard, B. V., & Magee, M. F. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0046-8 · Cited by 1,386
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
Waagstein, F., Hjalmarson, Å. C., Swedberg, K. B., Bristow, M. R., Gilbert, E. M., Camerini, F., Fowler, M. B., Silver, M. A., Johnson, M. R., & Goss, F. (1993) · The Lancet · doi:10.1016/0140-6736(93)92930-r · Cited by 1,223
Research works printed but not linked: 2
- Mohacsi, 2001, Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study, Circulation, 104, II-754
- Chavey, 2001, Guideline for the management of heart failure caused by systolic dysfunction, Am Fam Physician, 64, 1045
Cited by
Sorted by citations
Items 101–194 of 194
Bucindolol: A Pharmacogenomic Perspective on its Use in Chronic Heart Failure
Smart, N. A., Kwok, N., Holland, D. J., Jayasighe, R., & Giallauria, F. (2011) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s4309 · Cited by 15
Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells
Onay-Beşikçi, A., Süzmeçelik, E., & Ozcelikay, A. T. (2012) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y2012-015 · Cited by 15
Infective endocarditis--an Indian perspective.
Ss, K., Ramakrishnan, S., & Vk, B. (2005) · PubMed · Cited by 14
Association between higher rates of cardioprotective drug use and survival in patients on dialysis
Tang, Y., Brooks, J. M., Wetmore, J. B., & Shireman, T. I. (2014) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2014.12.007 · Cited by 13
Infusino, F., Pitocco, D., Zaccardi, F., Scalone, G., Coviello, I., Nerla, R., Mollo, R., Sestito, A., Monaco, A. D., Barone, L., et al. (2010) · PubMed · Cited by 13
Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure
Sindaco, D. D., Pulignano, G., Cioffi, G., Tarantini, L., Lenarda, A. D., Feo, S. D., Opasich, C., Minardi, G., Giovannini, E., & Leggio, F. (2007) · Journal of Cardiovascular Medicine · doi:10.2459/01.jcm.0000285316.71057.26 · Cited by 13
GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M. J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2007-3-5-88-111 · Cited by 13
Wang, M., Lv, Q., Zhao, L., Wang, Y., Luan, Y., Li, Z., Fu, G., & Zhang, W. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8312 · Cited by 12
Diabetes Mellitus and Cardiovascular Disease
Chyun, D. A., & Young, L. H. (2006) · Nursing Clinics of North America · doi:10.1016/j.cnur.2006.07.007 · Cited by 12
Girerd, N., Zannad, F. M., & Rossignol, P. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.06.004 · Cited by 12
Optimizing treatment of diabetes and cardiovascular disease with combined α,β‐blockade
Bell, D. S. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x53306 · Cited by 12
Treatment of Diabetes in People with Heart Failure
Howlett, J. G., & MacFadyen, J. C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.036 · Cited by 12
Fu, Q., Hu, Y., Wang, Q., Liu, Y., Li, N., Xu, B. Y., Kim, S., Chiamvimonvat, N., & Xiang, Y. K. (2016) · The Journal of Physiology · doi:10.1113/jp273314 · Cited by 11
Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets.
Cong, S., Ramachandra, C. J. A., Ja, K. P. M. M., Yap, J., SHIM, W. S. N., Wei, L., & Hausenloy, D. J. (2020) · PubMed · Cited by 13
García‐García, C., Lupón, J., Urrútia, A., González, B., Herreros, J., Altimir, S., Coll, R., Prats, M., Rey‐Joly, C., & Valle, V. (2005) · Medicina Clínica · doi:10.1157/13077138 · Cited by 11
Meindl, C., Hochadel, M., Frankenstein, L., Bruder, O., Pauschinger, M., Hambrecht, R., von Scheidt, W., Pfister, O., Hartmann, A., Maier, L. S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234260 · Cited by 10
VersorgungsLeitlinie, N. (2013) · Cited by 9
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Integrating heart failure guidelines into clinical practice
Swedberg, K. B., & Ekman, I. (2005) · European Heart Journal Supplements · doi:10.1093/eurheartj/sui059 · Cited by 9
Cook, R. F., Bussey, C. T., Mellor, K. M., Cragg, P. A., & Lamberts, R. R. (2017) · Experimental Physiology · doi:10.1113/ep086293 · Cited by 9
Krum, H., Meehan, A., Varigos, J., Loane, P., & Billah, B. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00529.x · Cited by 9
Management of patients with type 2 diabetes after acute coronary syndromes
Bartnik, M., Malmberg, K., & Rydén, L. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.022 · Cited by 8
Pharmacologic management of patients with both heart failure and diabetes
MacDonald, M. R., Petrie, M. C., Fisher, M., & McMurray, J. J. V. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0019-3 · Cited by 8
Double trouble: managing diabetic emergencies in patients with heart failure
Philip, L., & Poole, R. (2018) · Practical Diabetes · doi:10.1002/pdi.2181 · Cited by 8
Anfinogenova, Y., Grakova, E. V., Shvedova, M., Kopeva, K. V., Teplyakov, A. T., & Popov, S. V. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9647-y · Cited by 8
Gil-Ortega, I., & Kaski, J. C. (2006) · Medicina Clínica · doi:10.1157/13094003 · Cited by 9
A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure
Iyngkaran, P., Toukhsati, S. R., Thomas, M. C., Jelinek, M. V., Hare, D. L., & Horowitz, J. D. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s38444 · Cited by 7
Schwartz, B., Pierce, C., Madelaire, C., Schou, M., Kristensen, S. L., Gislason, G., Køber, L., Torp-Pedersen, C. T., & Andersson, C. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021310 · Cited by 7
Masarone, D., Pacileo, R., & Pacileo, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10189-4 · Cited by 7
The role of glycemia in acute heart failure patients
Seferović, J. P., Milinković, I., Tesic, M. B., Ristić, A. D., Lalic, N. M., Simeunović, D. S., Živković, I., Somma, S. D., & Seferovic, P. M. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0239 · Cited by 7
Larijani, B. A., Afshari, M., Astanehi-Asghari, F., Mojtahedi, A., Rezaie, A. R., Hossein‐Nezhad, A., Heshmat, R., Mohammadirad, A., & Abdollahi, M. R. (2005) · Therapy · doi:10.1586/14750708.3.1.119 · Cited by 7
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives
Khattab, E., Kyriakou, M., Leonidou, E., Sokratous, S., Mouzarou, A., Myrianthefs, M. M., & Kadoglou, N. P. E. (2025) · Pharmaceuticals · doi:10.3390/ph18010134 · Cited by 7
Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications
Chow, C., Mentz, R. J., & Greene, S. J. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00512-3 · Cited by 6
Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes
Bussey, C. T., Babakr, A. A., Iremonger, R. R., van Hout, I., WILKINS, G. T., Lamberts, R. R., & Erickson, J. R. (2020) · Physiological Reports · doi:10.14814/phy2.14394 · Cited by 6
Sackner‐Bernstein, J. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.01.029 · Cited by 6
Subramanian, U., Kamalesh, M., Temkit, M., Eckert, G. J., & Sawada, S. G. (2009) · American Journal of Cardiovascular Drugs · doi:10.2165/1006180-000000000-00000 · Cited by 5
Dave, C. V., Strom, B. L., Kobylarz, F. A., Horton, D. B., Gerhard, T., Tseng, C., Dejanovic, I., Nyandege, A. N., & Setoguchi, S. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5303 · Cited by 5
Nicklas, J. M., Bleske, B. E., Harrison, R. V., Hogikyan, R. V., Kwok, Y. S., & Chavey, W. E. (2013) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.010 · Cited by 5
Metoprolol rescues endothelial progenitor cell dysfunction in diabetes
Yan, L., Dong, Y.-F., Qing, T.-L., Deng, Y., Han, X., Shi, W., Li, J.-F., Gao, F., Zhang, X., Tian, Y., et al. (2020) · PeerJ · doi:10.7717/peerj.9306 · Cited by 5
Tobing, D., French, J. K., Varigos, J., Meehan, A., Billah, B., Krum, H., & the post‐MI audit group (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01594.x · Cited by 5
The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure
Freitas, O. D., Lenz, O., Fornoni, A., & Materson, B. J. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.2.139 · Cited by 5
Heart Failure in Diabetes Mellitus: An Updated Review
Sohrabi, C., Saberwal, B., Lim, W. Y., Tousoulis, D., Ahsan, S., & Παπαγεωργίου, Ν. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118091659 · Cited by 5
Carvedilol: β-Blockade and Beyond
Stroe, A. F., & Gheorghiade, M. (2004) · Reviews in Cardiovascular Medicine · Cited by 5
Pastormerlo, L. E., Mammini, C., Giannoni, A., Valleggi, A., Prontera, C., Gabutti, A., Poletti, R., Padeletti, L., Emdin, M., & Passino, C. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000159 · Cited by 4
Beta-blocker contraindications: Are there patients or situations where use is inappropriate?
Naik, S. D., & Freudenberger, R. S. (2007) · Current Heart Failure Reports · doi:10.1007/s11897-007-0006-5 · Cited by 2
Echeverría, L. E., Saldarriaga, C., Campbell‐Quintero, S., Morales-Rodríguez, L. N., de León, J. D. L., Buitrago, A. F., Martínez-Carreño, E. M., Sandoval-Luna, J. A., Llamas, A., Moreno-Silgado, G. A., et al. (2024) · Biomédica · doi:10.7705/biomedica.6951 · Cited by 3
Treatment of Diabetes in People with Heart Failure
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.028 · Cited by 2
Matowa, P. R. (2015) · Pharmacology & Pharmacy · doi:10.4236/pp.2015.65029 · Cited by 2
Beta Blockade in Diabetic Heart Failure
Lukas, M. A. (2006) · Heart Failure Clinics · doi:10.1016/j.hfc.2005.11.005 · Cited by 2
Erdmann, E. (2012) · Der Internist · doi:10.1007/s00108-012-3015-8 · Cited by 2
Marx, N., CHENG, A. Y. Y., Agarwal, R., Greene, S. J., & Abu-Hantash, H. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac114 · Cited by 2
Buchhorn, R., & Ross, R. (2014) · Reviews on Recent Clinical Trials · doi:10.2174/157488710902141009103818 · Cited by 2
Beta‐Blockers for Treatment of Heart Failure in the Elderly
Zimmet, H., & Krum, H. (2006) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2006.tb00615.x · Cited by 1
Rosa, G. M., Meliota, G., Brunelli, C., & Ferrero, S. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1291631 · Cited by 1
Makolkin, V. I. (2005) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2005-11-3-149-153 · Cited by 1
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?
Monami, M., & Mannucci, E. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0465-2 · Cited by 1
Место бета-блокаторов в лечении артериальной гипертензии в 2017 году: так ли все плохо?
Radchenko, G. (2017) · HYPERTENSION · doi:10.22141/2224-1485.2.52.2017.101292 · Cited by 1
Yamashina, A., Nishikori, M., Fujimito, H., & Oba, K. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101141 · Cited by 1
Mental Disorders: Burden of disease and cost-effectiveness
Vos, T. (2006) · RePub (Erasmus University Rotterdam) · Cited by 1
Norhammar, A., Johansson, I., Thrainsdottir, I. S., & Rydén, L. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch45 · Cited by 1
AMPK and TET2 Signaling Pathway and their Natural ActivatorsPreprint
Patil, S., Sharma, R., Sharma, U. K., & Padwad, Y. S. (2022) · Preprints.org · doi:10.20944/preprints202204.0100.v1
Update: Therapie der chronischen Herzinsuffizienz
Auer, J. (2009) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Diabetes mellitus und Herzinsuffizienz
Pfister, R., & Schneider, C. A. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0707-y
Traitement du diabète chez les personnes atteintes d'insuffisance cardiaque
Howlett, J. G., & MacFadyen, J. C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.019
Les bêtabloquants restent précieux, mais…
Danchin, N., Chaïb, A., Lepillier, A., & Durand, É. (2008) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(08)70423-1
Schneider, C. A. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0705-0
Rydén, L., Grant, P. J., Bax, J. J., Fagard, R. H., Ferrari, R., Hasdai, D., Hoes, A. W., Kirchhof, P. F., Piepoli, M. F., Torbicki, A., et al. (2014)
Diabetic Cardiomyopathy: From Pathophysiology
Gatzoulis, K. A. (2014)
Heart Failure and Cardiac Dysfunction in Diabetes
Young, L. H., Russell, R. R., & Chyun, D. A. (2005) · Humana Press eBooks · doi:10.1385/1-59259-908-7:555
da Rosa, P. R., Vaccari, E., Chanan, J. A., Brust, L. G., Souza, G. C., Goldraich, L. A., Clausell, N., Biolo, A., & Alegre, P. (2012)
The patient with CHF and diabetes
Gardner, R. S., McDonagh, T. A., & Walker, N. L. (2014) · doi:10.1093/med/9780199674152.003.0017
Inhibition of the Sympathetic Nervous System
Kransdorf, E. P., & Steidley, D. E. (2017) · Springer eBooks · doi:10.1007/978-1-4471-4219-5_6
Givertz, M. M., & Stewart, G. C. (2009) · doi:10.1002/9781444309768.ch76
Tratamiento de la insuficiencia cardiaca en el paciente diabético: ¿Cuáles son las diferencias?
Echeverría, L. E., & Gallego, C. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2019.12.002
7. Diabetes and Heart Failure: How to Treat Doubles Dangers
Ito, H. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.147a
Capitão, E. F. M. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/rf8p-sv82
Thrainsdottir, I. S., & Rydén, L. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch41
7. Diabetes and Heart Failure: How to Treat Doubles Dangers
Ito, H. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.1902
Traitement du diabète chez les personnes atteintes d'insuffisance cardiaque
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.03.429
Pfister, R., & Schneider, C. A. (2008) · Springer eBooks · doi:10.1007/978-3-540-79011-2_30
Pfister, R., & Schneider, C. A. (2011) · Springer eBooks · doi:10.1007/978-3-642-16481-1_30
Heart Failure and Cardiac Dysfunction in Diabetes
Afari, M. E., & Givertz, M. M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_27
Beta-blocker therapy among patients with heart failure
Singh, R. B., Fedačko, J., Moshiri, A., Moshiri, M., Shogenova, L. V., Chuchalin, A. G., Chibisov, S. M., Kharlitskaya, E. V., Omar, O., & Gushchina, Y. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822972-9.00033-x
van Teeffelen, W. M. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8543-0_19
Inhibition of the Sympathetic Nervous System
Forst, B. J., & Steidley, D. E. (2026) · Springer eBooks · doi:10.1007/978-3-032-12626-9_7
Studies of the Epidemiology and Prognosis of Patients with Heart Failure in Leicestershire
Newton, J. D. (2009) · Leicester Research Archive (University of Leicester)
Diabetes: prevention of cardiovascular events.
Sigal, R. J., Malcolm, J., & Arnaout, A. (2006) · PubMed Central
Metadata
- Authors
- Haas, S. J., Vos, T., Gilbert, R. E., & Krum, H.
- Affiliations
- The Alfred Hospital (AU)
- The University of Melbourne (AU)
- Corresponding author
- Krum, Henry
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2003-11
- Volume
- 146
- Issue
- 5
- Pages
- 848-853
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W1975966089
- Cited by
- 194
- References
- 41
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 7 · 2020: 18 · 2019: 10 · 2018: 6 · 2017: 9 · 2016: 8 · 2015: 7 · 2014: 12 · 2013: 12 · 2012: 8
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- beta-blockers, chronic heart failure, diabetes mellitus, all-cause mortality, carvedilol, bisoprolol, metoprolol, beta-blocker contraindication, comorbidities
- MeSH terms
- Adrenergic beta-Antagonists, Diabetes Mellitus, Heart Failure, Humans, Comorbidity, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
